Erasca, Inc. (ERAS): who owns it and who trades it
As of Nov 16, 2026, ERAS insiders reported 3 open-market sales worth $2.3M and no purchases in the last 12 months, with 0% of the sale value made under pre-set 10b5-1 plans. The largest seller was Ebun Garner (General Counsel & Corp. ), with $2M. 5 of the 50 famous funds we follow held it at their last quarter end.
Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Who is buying and selling Erasca
From the latest filingsOverall: about as much buying as selling. Insiders mostly sold. Funds and famous investors mostly bought.
Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.
Who owns ERAS
258 funds and institutions reported ERAS shares worth $5.4B at the end of Q2 2026, about 92% of the company. The largest holder is Frazier Life Sciences Management, L.P. with 8.0%.
Funds and institutions (13F) 92%Everyone else 8%
10 largest owners, by share of the company
Top 20 owners
| Owner | Shares | % of company | Value | Change since Q1 2026 |
|---|---|---|---|---|
| Frazier Life Sciences Management, L.P. | 24.98M | 8.04% | $458M | +1% |
| T. Rowe Price Investment Management, Inc. | 21.19M | 6.82% | $388M | -0% |
| BlackRock, Inc. | 21.15M | 6.81% | $388M | +5% |
| Rtw Investments, LP | 17.95M | 5.77% | $329M | +11% |
| Venrock Adviser, LLC | 17.89M | 5.76% | $328M | +9% |
| State Street Corp | 12.18M | 3.92% | $223M | +31% |
| Logos Global Management LP | 12.15M | 3.91% | $223M | +9% |
| Vanguard Capital Management LLC | 11.40M | 3.67% | $209M | +1% |
| Siren, L.L.C. | 11.40M | 3.67% | $209M | +1% |
| Paradigm Biocapital Advisors LP | 9.55M | 3.07% | $175M | -8% |
| ARCH Venture Management, LLC | 7.09M | 2.28% | $130M | No change |
| Geode Capital Management, LLC | 6.50M | 2.09% | $119M | +8% |
| T. Rowe Price Associates | 6.27M | 2.02% | $115M | +246% |
| Cormorant Asset Management, LP | 6.00M | 1.93% | $110M | +3% |
| Affinity Asset Advisors, LLC | 5.25M | 1.69% | $96.2M | -2% |
| Vivo Capital, LLC | 4.13M | 1.33% | $75.6M | -66% |
| Alliancebernstein L.P. | 4.12M | 1.33% | $66.6M | – |
| Goldman Sachs Group Inc | 3.82M | 1.23% | $70M | -22% |
| California State Teachers Retirement System | 3.23M | 1.04% | $176M | +1480% |
| Bank of America Corp | 3.05M | 0.98% | $55.9M | -0% |
From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.
Insider trades
In the last 12 months, ERAS insiders reported $0 of open-market purchases and $2.3M of sales. 0% of the sale value was under a 10b5-1 plan, a schedule set up in advance.
Purchases and sales by month
Latest trades
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Apr 1, 2026 | Ebun Garner | Chief Legal Officer | Sale | 80,000 | $16.40 | $1.3M | Form 4 |
| Mar 4, 2026 | Shannon Morris | Chief Medical Officer | Sale | 20,000 | $15.04 | $301K | Form 4 |
| Jan 7, 2026 | Ebun Garner | General Counsel & Corp. | Sale | 120,000 | $5.59 | $671K | Form 4 |
Insiders by value traded
| Insider | Role | Bought | Sold | Last trade |
|---|---|---|---|---|
| Ebun Garner | General Counsel & Corp. Sec. | – | $2M | Apr 1, 2026 |
| Shannon Morris | Chief Medical Officer | – | $301K | Mar 4, 2026 |
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
ERAS short interest
High short interest. 10.6% of ERAS shares are sold short: about 1 share in 9. Over the last 12 reports the number of shares short went up 18%.
As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.
As of Oct 30, 2026, 37.16M ERAS shares were sold short, 10.6% of the shares outstanding, up 0.5% from the report before. At the average daily volume of 4.18M shares, buying them all back would take about 8.9 trading days (days to cover).
Shares short, % of all shares
Days to cover
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 37.16M | 10.62% | +1% | 4.18M | 8.9 |
| Oct 15, 2026 | 36.96M | 10.57% | +5% | 5.82M | 6.3 |
| Sep 30, 2026 | 35.34M | 10.10% | +7% | 5.14M | 6.9 |
| Sep 15, 2026 | 33.04M | 9.45% | +6% | 4.32M | 7.7 |
| Aug 31, 2026 | 31.24M | 8.93% | +1% | 3.31M | 9.4 |
| Aug 14, 2026 | 30.85M | 8.82% | +3% | 3.08M | 10.0 |
| Jul 31, 2026 | 29.95M | 9.64% | -3% | 4.12M | 7.3 |
| Jul 15, 2026 | 30.77M | 9.90% | -5% | 5.23M | 5.9 |
| Jun 30, 2026 | 32.32M | 10.40% | +3% | 7.19M | 4.5 |
| Jun 15, 2026 | 31.49M | 10.13% | -1% | 5.46M | 5.8 |
| May 29, 2026 | 31.89M | 10.26% | +1% | 4.26M | 7.5 |
| May 15, 2026 | 31.43M | 10.11% | -2% | 4.67M | 6.7 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
Erasca company events
Erasca filed 16 reports on Form 8-K in the last 12 months, 2 of them about an important change (leadership). The latest was on Oct 16, 2026.
- Oct 16, 2026LeadershipErasca, Inc. (the Company) decided to realign its leadership responsibilities to support the development and potential commercialization of its RAS-targeting programs. Filing
- Aug 24, 2026AnnouncementErasca, Inc. announced that the U.S. Food and Drug Administration has granted Fast Track Designation to ERAS-0015 for the treatment of patients with metastatic pancreatic adenocarcinoma. Filing
- Aug 11, 2026ResultsReleased financial results. Filing
- Aug 10, 2026LeadershipCharles S. Fuchs, M.D., M.P.H., was appointed President, Research & Development of Erasca, Inc. Filing
- Jul 14, 2026AnnouncementErasca, Inc. entered into an underwriting agreement with J.P. Morgan Securities LLC, Morgan Stanley & Co. LLC, Jefferies LLC and Evercore Group L.L.C., as representatives of the several underwriters named therein, relating to the issuance and sale of 31,428,572 shares of the Company’s common stock… Filing
- Jul 13, 2026AnnouncementErasca, Inc. announced updated preliminary Phase 1 data for its potentially best-in-class, pan-RAS molecular glue ERAS-0015 in patients with RAS-mutant solid tumors. Filing
- Jul 1, 2026VoteReported shareholder vote results. Filing
- May 11, 2026ResultsReleased financial results. Filing
- Apr 27, 2026AnnouncementErasca, Inc. announced positive preliminary Phase 1 dose escalation data for its potentially best-in-class, pan-RAS molecular glue ERAS-0015 in patients with RAS-mutant solid tumors. Filing
- Apr 27, 2026AnnouncementThe Company received a letter from legal counsel for Revolution Medicines, Inc. Filing
- Apr 21, 2026AnnouncementErasca, Inc. narrowed the time period for the anticipated Phase 1 monotherapy data readout for the Company’s pan-RAS molecular glue ERAS-0015 from the AURORAS-1 and JYP0015M101 clinical trials to no later than mid-May of 2026, from the prior guidance of the first half of 2026. Filing
- Mar 12, 2026ResultsReleased financial results. Filing
- Jan 29, 2026AnnouncementErasca, Inc. disclosed that its cash, cash equivalents and marketable securities for the Company as of December 31, 2025 was approximately $341.8 million. Filing
- Jan 22, 2026AnnouncementErasca, Inc. entered into an underwriting agreement with J.P. Morgan Securities LLC, Morgan Stanley & Co. LLC, Jefferies LLC and Evercore Group L.L.C., as representatives of the several underwriters named therein, relating to the issuance and sale of 22,500,000 shares of the Company’s common stock… Filing
- Jan 20, 2026ResultsReleased financial results. Filing
- Jan 12, 2026AnnouncementThe Company announced clinical progress for its RAS-targeting franchise and 2026-2027 milestones. Filing
From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week
Erasca financials
Famous investors that hold ERAS
5 of the 50 well-known investors we track reported holding ERAS in their latest 13F filing. The largest position is Jim Simons's, worth $23.6M.
Position size
All holders
| Fund | Quarter | Shares | Value | Of portfolio | Change |
|---|---|---|---|---|---|
| Jim Simons · Renaissance Technologies | Q3 2026 | 1.61M | $23.6M | 0.0% | +18% |
| Israel Englander · Millennium Management | Q3 2026 | 600,437 | $8.8M | 0.0% | -34% |
| Ken Griffin · Citadel Advisors | Q3 2026 | 591,644 | $8.7M | 0.0% | +524% |
| Paul Tudor Jones · Tudor Investment Corp | Q3 2026 | 64,796 | $950K | 0.0% | New |
| George Soros · Soros Fund Management | Q3 2026 | 52,001 | $762K | 0.0% | New |
From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.
5%+ stakes filed in the last 120 days
Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 4 filings named ERAS in the last 120 days.
| Filed | Holder | Form | Stake |
|---|---|---|---|
| Nov 16, 2026 | RTW Investments, LP | 13G/A | 6.4% |
| Nov 16, 2026 | T. Rowe Price Investment Management, Inc. | 13G/A | 4.9% |
| Nov 16, 2026 | RTW Investments, LP | 13G/A | 6.4% |
| Nov 16, 2026 | T. Rowe Price Investment Management, Inc. | 13G/A | 4.9% |
Questions about Erasca, Inc. (ERAS) stock
Who owns the most ERAS stock?
The largest reported owner of Erasca, Inc. (ERAS) is Frazier Life Sciences Management, L.P., with 8.0% of the company. In total, 258 funds and institutions reported holding ERAS at the end of Q2 2026, together about 92% of the shares. See the largest owners.
Are ERAS insiders buying or selling?
In the last 12 months, ERAS insiders reported no open-market purchases and 3 sales worth $2.3M. The latest trade was on Apr 1, 2026. See every trade.
What is the short interest in ERAS?
As of Oct 30, 2026, 37.16M ERAS shares were sold short, 10.6% of the shares outstanding, up 0.5% from the report before. At the average daily volume of 4.18M shares, buying them all back would take about 8.9 trading days (days to cover). See the history.
Which famous investors hold ERAS?
5 of the 50 well-known investors we track reported ERAS in their latest 13F filing, including Jim Simons, Israel Englander, Ken Griffin. The largest position is worth $23.6M. See all holders.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.